Becton, Dickinson and (BDX) 10-Q2 Feb 232023 Q1 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page	3 Months Ended
Cover Page	Dec. 31, 2022 shares
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-4802
Entity Registrant Name	Becton, Dickinson and Company
Entity Central Index Key	0000010795
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07417-1880
City Area Code	(201)
Local Phone Number	847-6800
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	283,901,642
Common Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
Redeemable Preferred Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B
Trading Symbol	BDXB
Security Exchange Name	NYSE
Notes 1.900% due December 15, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
Notes 1.401% due May 24, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.401% Notes due May 24, 2023
Trading Symbol	BDX23A
Security Exchange Name	NYSE
Notes 3.020% due May 24, 2025 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
Notes 0.632% due June 4, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.632% Notes due June 4, 2023
Trading Symbol	BDX/23A
Security Exchange Name	NYSE
Notes 1.208% due June 4, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE
Notes 1.213% Notes due February 12, 2036 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.213% Notes due February 12, 2036
Trading Symbol	BDX/36
Security Exchange Name	NYSE
Notes 0.000% due August 13, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.000% Notes due August 13, 2023
Trading Symbol	BDX23B
Security Exchange Name	NYSE
Notes 0.034% due August 13, 2025 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.034% Notes due August 13, 2025
Trading Symbol	BDX25A
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 4,586	$ 4,718
Cost of products sold	2,453	2,498
Selling and administrative expense	1,187	1,185
Research and development expense	313	314
Acquisition-related integration and restructuring expense	44	34
Other operating expense (income), net	3	(4)
Total Operating Costs and Expenses	4,001	4,027
Operating Income	585	692
Interest expense	(102)	(98)
Interest income	6	2
Other (expense) income, net	(8)	4
Income from Continuing Operations Before Income Taxes	481	600
Income tax (benefit) provision	(28)	32
Net Income from Continuing Operations	509	568
Income from Discontinued Operations, Net of Tax	0	109
Net Income	509	677
Preferred stock dividends	(23)	(23)
Net income applicable to common shareholders	$ 486	$ 655
Income from Continuing Operations, Basic (USD per share)	$ 1.71	$ 1.92
Income from Discontinued Operations, Basic (USD per share)	0	0.38
Basic Earnings per Share (USD per share)	1.71	2.30
Income from Continuing Operations, Diluted (USD per share)	1.70	1.90
Income from Discontinued Operations, Diluted (USD per share)	0	0.38
Diluted Earnings per Share (USD per share)	1.70	2.28
Dividends per Common Share (USD per share)	$ 0.91	$ 0.87

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net Income	$ 509	$ 677
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(80)	41
Defined benefit pension and postretirement plans	11	11
Cash flow hedges	(3)	(7)
Other Comprehensive (Loss) Income, Net of Tax	(72)	45
Comprehensive Income	$ 437	$ 722

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022
Current Assets:
Cash and equivalents	$ 612	$ 1,006
Restricted cash	133	153
Short-term investments	0	8
Trade receivables, net	2,282	2,191
Inventories:
Materials	809	707
Work in process	443	397
Finished products	2,352	2,120
Inventories	3,604	3,224
Prepaid expenses and other	1,545	1,559
Total Current Assets	8,175	8,141
Property, Plant and Equipment	12,926	12,415
Less allowances for depreciation and amortization	6,679	6,402
Property, Plant and Equipment, Net	6,247	6,012
Goodwill	24,763	24,621
Developed Technology, Net	8,874	9,108
Customer Relationships, Net	2,599	2,683
Other Intangibles, Net	517	519
Other Assets	1,955	1,848
Total Assets	53,129	52,934
Current Liabilities:
Current debt obligations	2,188	2,179
Payables, accrued expenses and other current liabilities	5,437	5,632
Total Current Liabilities	7,625	7,811
Long-Term Debt	14,268	13,886
Long-Term Employee Benefit Obligations	902	902
Deferred Income Taxes and Other Liabilities	4,862	5,052
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2	2
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 364,639,901 shares in December 31, 2022 and September 30, 2022	365	365
Capital in excess of par value	19,590	19,553
Retained earnings	15,384	15,157
Deferred compensation	24	23
Treasury stock	(8,333)	(8,330)
Accumulated other comprehensive loss	(1,559)	(1,488)
Total Shareholders’ Equity	25,472	25,282
Total Liabilities and Shareholders’ Equity	$ 53,129	$ 52,934

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Sep. 30, 2022
Statement of Financial Position [Abstract]
Common stock, par value (USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	364,639,901	364,639,901

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities
Net income	$ 509	$ 677
Income from Discontinued Operations, Net of Tax	0	109
Net Income from Continuing Operations	509	568
Adjustments to net income from continuing operations to derive net cash provided by continuing operating activities:
Depreciation and amortization	567	546
Share-based compensation	89	81
Deferred income taxes	(118)	(69)
Change in operating assets and liabilities	(665)	(300)
Pension obligation	21	(144)
Other, net	(3)	(152)
Net Cash Provided by Continuing Operating Activities	399	530
Investing Activities
Capital expenditures	(208)	(183)
Acquisitions, net of cash acquired	0	(415)
Other, net	(83)	(84)
Net Cash Used for Continuing Investing Activities	(291)	(682)
Financing Activities
Change in short-term debt	365	0
Payments of debt	(528)	0
Dividends paid	(281)	(271)
Other, net	(89)	(56)
Net Cash Used for Continuing Financing Activities	(534)	(327)
Net cash provided by operating activities	0	144
Net cash used for investing activities	0	(4)
Net Cash Provided by Discontinued Operations	0	140
Effect of exchange rate changes on cash and equivalents and restricted cash	11	(6)
Net decrease in cash and equivalents and restricted cash	(415)	(345)
Opening Cash and Equivalents and Restricted Cash	1,159	2,392
Closing Cash and Equivalents and Restricted Cash	$ 744	$ 2,047

Basis of Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2022 Annual Report on Form 10-K. On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company. The historical results of the Diabetes Care business (previously included in BD’s Medical segment) that was contributed to Embecta Corp (“Embecta”) in the spin-off, as well as interest expense related to indebtedness incurred by Embecta prior to the spin-off date, have been reflected as discontinued operations in the Company’s condensed consolidated financial statements for the three months ended December 31, 2021. Additional disclosures regarding the spin-off are provided in Note 2. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Spin-Off of Embecta Corp.

Spin-Off of Embecta Corp.	3 Months Ended
Spin-Off of Embecta Corp.	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Spin-Off of Embecta Corp.	Spin-Off of Embecta Corp. On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta through a distribution of Embecta’s publicly traded common stock (listed on NASDAQ under the ticker symbol “EMBC”) to BD’s shareholders of record as of the close of business on March 22, 2022 (the “record date”). The Company distributed one share of Embecta common stock for every five common shares of BD outstanding as of the record date and shareholders received cash in lieu of fractional shares of Embecta common stock. BD retained no ownership interest in Embecta subsequent to the spin-off. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The Company and Embecta entered into various agreements to effect the spin-off and provide a framework for the relationship between the Company and Embecta after the spin-off. Such agreements include the separation and distribution agreement, as well as the following ongoing agreements: a cannula supply agreement, an intellectual property matters agreement, a transition services agreement, manufacturing and supply agreements, a lease agreement, a distribution agreement to support commercial operations, a logistics services agreement and other agreements including an employee matters agreement and a tax matters agreement. Under these agreements, the Company will continue to provide certain products and services to Embecta following the spin-off. The agreements do not provide the Company with the ability to influence the operating or financial policies of Embecta subsequent to the spin-off date. Amounts included in the Company’s condensed consolidated statements of income during the three months ended December 31, 2022 as a result of these agreements were immaterial. . Details of Income from Discontinued Operations, Net of Tax are as follows: Three Months Ended Millions of dollars 2021 Revenues $ 277 Cost of products sold 74 Selling and administrative expense 38 Research and development expense 15 Other operating expense, net 26 Total Operating Costs and Expenses 153 Operating Income 123 Interest expense — Other income, net — Income from Discontinued Operations Before Income Taxes 123 Income tax provision 14 Income from Discontinued Operations, Net of Tax $ 109 During the three months ended December 31, 2021, the Company incurred $25 million of separation costs, including those for consulting, legal, tax and other advisory services associated with the spin-off, which were previously recorded within Other operating expense (income), net and are now included as a component of Income from Discontinued Operations, Net of Tax. The Company’s Revenues and Cost of products sold from continuing operations were recast to reflect previously eliminated intercompany transactions that occurred between BD and Embecta and that resulted in a third-party sale in the same period. The impacts of these transactions to Embecta are also reflected as a component of Income from Discontinued Operations, Net of Tax

Shareholders' Equity

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders' Equity Changes in certain components of shareholders' equity for the first quarters of fiscal years 2023 and 2022 were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2022 $ 365 $ 19,553 $ 15,157 $ 23 (81,283) $ (8,330) Net income — — 509 — — — Common dividends ($0.91 per share) — — (259) — — — Preferred dividends — — (23) — — — Common stock issued for share-based compensation and other plans, net — (52) — — 556 (3) Share-based compensation — 89 — — — — Common stock held in trusts, net (a) — — — — (11) — Balance at December 31, 2022 $ 365 $ 19,590 $ 15,384 $ 24 (80,738) $ (8,333) Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) Net income — — 677 — — — Common dividends ($0.87 per share) — — (248) — — — Preferred dividends — — (23) — — — Common stock issued for share-based compensation and other plans, net — (71) — — 762 19 Share-based compensation — 83 — — — Common stock held in trusts, net (a) — — — — (5) — Repurchase of common stock (b) — 150 — — (462) (150) Balance at December 31, 2021 $ 365 $ 19,435 $ 14,233 $ 24 (79,869) $ (7,855) (a) Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) Represents shares received upon final settlement of an accelerated share repurchase agreement, and the related forward sale contract, entered into during the fourth quarter of fiscal year 2021. T he share repurchases were made pursuant to the repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, for which there is no expiration date. In November 2021, the Board of Directors authorized the Company to repurchase up to an additional 10 million shares of BD common stock, for which there is also no expiration date. The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2023 and 2022 were as follows: (Millions of dollars) Total Foreign Currency Benefit Plans Cash Flow Hedges Balance at September 30, 2022 $ (1,488) $ (987) $ (574) $ 75 Other comprehensive loss before reclassifications, net of taxes (84) (80) — (4) Amounts reclassified into income, net of taxes 12 — 11 1 Balance at December 31, 2022 $ (1,559) $ (1,067) $ (563) $ 73 (Millions of dollars) Total Foreign Currency Benefit Plans Cash Flow Hedges Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10) Other comprehensive income (loss) before reclassifications, net of taxes 34 41 — (7) Amounts reclassified into income, net of taxes 11 — 11 — Balance at December 31, 2021 $ (2,043) $ (1,251) $ (774) $ (17) The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2022 and 2021 included net (losses) gains relating to net investment hedges. Disclosures regarding amounts the Company recognized in other comprehensive income relating to cash flow hedges during the three months ended December 31, 2022 and 2021 are provided in Note 11. The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications and for reclassifications out of Accumulated other comprehensive income (loss) relating to benefit plans and cash flow hedges during the three months ended December 31, 2022 and 2021 were immaterial to the Company's consolidated financial results.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows: Three Months Ended 2022 2021 Average common shares outstanding 283,887 284,685 Dilutive share equivalents from share-based plans 1,453 2,038 Average common and common equivalent shares outstanding – assuming dilution 285,340 286,723 Share equivalents excluded from the diluted shares outstanding calculation: Mandatory convertible preferred stock (a) 5,899 5,965 Share-based plans (b) 1,374 730 (a) Excluded from the diluted shares outstanding calculation because the result would have been antidilutive. (b) Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.

Contingencies

Contingencies	3 Months Ended
Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (and in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. Product Liability Matters As of December 31, 2022, the Company is defending approximately 32,305 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court (“RI”) and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. • The first bellwether trial in the hernia MDL resulted in a complete defense verdict in favor of the Company in September 2021. • The second hernia MDL bellwether resulted in a $255 thousand verdict in April 2022. • The first bellwether trial in RI resulted in a $4.8 million verdict in August 2022, which the Company plans to appeal. Trials are currently scheduled in state and/or federal courts, including an additional bellwether trial in the MDL in May 2023. The Company also expects additional trials of Hernia Product Claims to take place over the next 12 months in RI, including trials in June 2023 and October 2023. The Company also continues to be a defendant in certain other mass tort litigation. As of December 31, 2022, the Company is defending product liability claims involving the Company’s line of pelvic mesh products, the majority of which are pending in various federal court jurisdictions and in a coordinated proceeding in New Jersey Superior Court. Also, as of December 31, 2022, the Company is defending product liability claims involving the Company’s line of inferior vena cava (“IVC”) filter products. The majority of those claims are pending in various federal court jurisdictions after having been remanded from the MDL in the United States District Court for the District of Arizona. In most product liability litigations like those described above, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. Other Legal Matters On February 27, 2020, a putative class action captioned Kabak v. Becton, Dickinson and Company, et al., Civ. No. 2:20-cv-02155 (SRC) (CLW), now captioned Industriens Pensionsforsikring v. Becton, Dickinson and Company, et al., was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers. The complaint, which purports to be brought on behalf of all persons (other than defendants) who purchased or otherwise acquired the Company's common stock from November 5, 2019 through February 5, 2020, asserts claims for purported violations of Sections 10 and 20 of the Securities Exchange Act of 1934 (“Exchange Act”) and Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder, and seeks, among other things, damages and costs. The complaint alleges that defendants concealed certain material information regarding Alaris TM infusion pumps, allegedly rendering certain public statements about the Company’s business, operations and prospects false or misleading, thereby allegedly causing investors to purchase stock at an inflated price. After an initial without prejudice dismissal, the plaintiff filed amended pleadings, which the Company in turn moved to dismiss. Ultimately, the court permitted certain aspects of the case to proceed. An answer with affirmative defenses was thereafter filed on October 3, 2022. Discovery has commenced and plaintiff’s motion for class certification was filed on January 17, 2023. The Company believes that it has strong defenses to the allegations that were not dismissed and it intends to defend itself vigorously. On November 2, 2020, a putative shareholder derivative action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, derivatively on behalf of the Company, against certain of the Company’s directors and officers. The complaint asserts claims for breach of fiduciary duty, violations of sections 10(b), 14(a) and 21D of the Exchange Act, and insider trading. The complaint principally alleges that the Company made misleading statements regarding Alaris TM infusion pumps in a proxy statement and other SEC filings. A second derivative action was filed on January 24, 2021, and the two actions were consolidated. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the derivative actions, and demanded, among other things, that the Board of Directors pursue claims against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands, communicating its determination to counsel for the shareholders. On January 10, 2023, one of the two shareholders referenced above filed a separate derivative action that: (i) is generally consistent with the shareholder letter and the two prior actions; and (ii) purports to challenge the reasonableness of the special committee’s process and determination. The Company believes that is has strong defenses to these claims and intends to defend itself vigorously. In May 2017, the Company was sued by a competitor in the Northern District of New York, alleging antitrust violations related to certain aspects of the Company’s medical delivery solutions business in a case captioned AngioDynamics, Inc. v. C. R. Bard, Inc. et al., Civ. No. 1:17-CV-0598. Trial began on September 19, 2022, resulting in a complete defense verdict for the Company on October 6, 2022, from which AngioDynamics has filed a notice of appeal. In February 2021, the Company received a subpoena from the Enforcement Division of the SEC requesting information from the Company relating to, among other things, Alaris TM infusion pumps. The Company is cooperating with the SEC and responding to these requests. The Company cannot anticipate the timing, scope, outcome or possible impact of the investigation, financial or otherwise. In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs for certain products, including Alaris TM and Pyxis TM devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government recently expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel. The Company is cooperating with the government and responding to these requests. In September 2021, the Company received a CID related to an inquiry initiated by the Northern District of Georgia in 2018. The requests concern sales and marketing practices with respect to certain aspects of the Company’s urology business. The government has made requests for documents and has interviewed employees. The inquiry is ongoing and the Company is cooperating with the government and responding to its requests. In September 2021, the Company was served with a complaint from the New Mexico Attorney General, alleging violations of the state’s consumer protection laws in connection with the sales and marketing of its IVC filters. The Company’s motion to dismiss certain of the claims was granted on May 10, 2022 and discovery is proceeding as to the remaining claims. The Company intends to vigorously defend itself in the litigation. As the case is in its early stages, the Company cannot anticipate the timing, scope, outcome or possible impact at present. The Company has been sued in state and federal courts in Georgia by plaintiffs who work or reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place. The plaintiffs in those cases seek compensatory and punitive damages. Pursuant to Georgia statute, punitive damages in these cases are generally capped at $250,000 per claimant. The cases allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO. The Company does not believe these cases are appropriate for class action treatment and they have not been filed as such. The Company currently has approximately 220 of such suits involving approximately 320 plaintiffs; approximately 45 of the cases also allege injury caused by exposure to a chemical of another defendant entirely unrelated to the Company. The Company has meritorious defenses and intends to defend itself vigorously and believes that future claims would generally face statute of limitations hurdles. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. The Company cannot predict the outcome of these other legal matters discussed above, nor can it predict whether any outcome will have a material adverse effect on the Company’s consolidated results of operations and/or consolidated cash flows. Accordingly, the Company has made no provisions for these other legal matters in its consolidated results of operations. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The Company also is subject to administrative proceedings under environmental laws in jurisdictions outside the U.S. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its consolidated results of operations and/or consolidated cash flows. Litigation Accruals The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.0 billion and $2.1 billion on December 31, 2022 and September 30, 2022, respectively. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.

Revenues

Revenues	3 Months Ended
Revenues	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The Company’s policies for recognizing sales have not changed from those described in the Company’s 2022 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Measurement of Revenues The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The Company’s rebate liability at December 31, 2022 and September 30, 2022 was $560 million and $525 million, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Effects of Revenue Arrangements on Consolidated Balance Sheets Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets. Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets. Remaining Performance Obligations The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $2.5 billion at December 31, 2022. The Company expects to recognize the majority of this revenue over the next three years. Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables, and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $1.9 billion at December 31, 2022. This revenue will be recognized over the customer relationship periods. Disaggregation of Revenues A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

Segment Data

Segment Data	3 Months Ended
Segment Data	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Data	Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. Prior to its spin-off on April 1, 2022, the Company reported the Diabetes Care business as an organizational unit within the Medical segment. As such, historical financial information of the Medical segment has been recast in the tables below to reflect the total segment revenues and revenues from continuing operations. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. See Note 2 for further information. Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues. Three Months Ended December 31, (Millions of dollars) 2022 2021 United States International Total United States International Total Medical Medication Delivery Solutions (a) $ 620 $ 419 $ 1,039 $ 620 $ 476 $ 1,096 Medication Management Solutions 564 142 706 484 143 627 Pharmaceutical Systems (a) 119 290 409 102 294 397 Total segment revenues $ 1,303 $ 852 $ 2,154 $ 1,207 $ 913 $ 2,120 Life Sciences Integrated Diagnostic Solutions $ 508 $ 445 $ 952 $ 615 $ 530 $ 1,145 Biosciences 137 212 349 129 209 338 Total segment revenues $ 645 $ 657 $ 1,302 $ 744 $ 739 $ 1,483 Interventional Surgery $ 287 $ 76 $ 363 $ 281 $ 80 $ 361 Peripheral Intervention 236 197 433 217 197 413 Urology and Critical Care 259 74 333 254 87 340 Total segment revenues $ 782 $ 347 $ 1,129 $ 752 $ 363 $ 1,115 Total revenues from continuing operations $ 2,730 $ 1,856 $ 4,586 $ 2,703 $ 2,016 $ 4,718 (a) Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta. Segment income for the three-month periods was as follows: Three Months Ended (Millions of dollars) 2022 2021 Income from Continuing Operations Before Income Taxes Medical $ 554 $ 572 Life Sciences 433 534 Interventional 301 265 Total Segment Operating Income 1,288 1,371 Acquisition-related integration and restructuring expense (44) (34) Net interest expense (96) (96) Other unallocated items (a) (667) (642) Total Income from Continuing Operations Before Income Taxes $ 481 $ 600

Benefit Plans

Benefit Plans	3 Months Ended
Benefit Plans	Dec. 31, 2022
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30. Net pension cost included the following components for the three-month periods: Three Months Ended (Millions of dollars) 2022 2021 Service cost $ 24 $ 35 Interest cost 35 20 Expected return on plan assets (38) (48) Amortization of prior service credit (2) (4) Amortization of loss 17 16 Settlements — 5 Net pension cost $ 36 $ 24 The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other (expense) income, net

Business Restructuring Charges

Business Restructuring Charges	3 Months Ended
Business Restructuring Charges	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Business Restructuring Charges	Business Restructuring Charges The Company incurred restructuring costs during the three months ended December 31, 2022, primarily in connection with the Company's simplification and other cost saving initiatives, which were recorded within Acquisition-related integration and restructuring expense . These simplification and other costs saving initiatives are focused on reducing complexity, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments. Restructuring liability activity for the three months ended December 31, 2022 was as follows: (Millions of dollars) Employee Other Total Balance at September 30, 2022 $ 24 $ 11 $ 35 Charged to expense 4 22 26 Cash payments (8) (18) (26) Non-cash settlements — (4) (4) Balance at December 31, 2022 $ 20 $ 11 $ 31

Intangible Assets

Intangible Assets	3 Months Ended
Intangible Assets	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets consisted of: December 31, 2022 September 30, 2022 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 15,136 $ (6,262) $ 8,874 $ 15,087 $ (5,979) $ 9,108 Customer relationships 4,859 (2,260) 2,599 4,853 (2,170) 2,683 Product rights 104 (79) 25 97 (72) 25 Trademarks 408 (160) 248 408 (155) 253 Patents and other 552 (355) 197 542 (346) 196 Amortized intangible assets $ 21,059 $ (9,116) $ 11,943 $ 20,987 $ (8,723) $ 12,264 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46 Intangible amortization expense for the three months ended December 31, 2022 and 2021 was $365 million and $355 million, respectively. The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2022 $ 10,909 $ 888 $ 12,824 $ 24,621 Purchase price allocation adjustments 3 — — 3 Currency translation 54 10 76 139 Goodwill as of December 31, 2022 $ 10,965 $ 898 $ 12,900 $ 24,763

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	3 Months Ended
Derivative Instruments and Hedging Activities	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at December 31, 2022 and September 30, 2022 were not material. The effects on the Company’s financial performance and cash flows are provided below. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments, such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts. The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2022 and September 30, 2022 were as follows: (Millions of dollars) Hedge Designation December 31, 2022 September 30, 2022 Foreign exchange contracts (a) Undesignated $ 1,639 $ 2,766 Foreign currency-denominated debt (b) Net investment hedges 1,801 2,140 Cross-currency swaps (c) Net investment hedges 1,473 910 (a) Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other (expense) income, net , during the three months ended December 31, 2022 and 2021 were immaterial to the Company's consolidated financial results. (b) Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (c) Represents cross-currency swaps which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss) . Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows: Three Months Ended (Millions of dollars) 2022 2021 Foreign currency-denominated debt $ (142) $ 49 Cross-currency swaps (80) 30 Interest Rate Risks and Related Strategies The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense, over the remaining life of the hedged debt. The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the three months ended December 31, 2022 and 2021, as well as the amounts expected to be reclassified within the next 12 months, are not material to the Company's consolidated financial results. Net after-tax losses and gains recorded in Other comprehensive income relating to interest rate hedges during the three months ended December 31, 2022 and 2021 were immaterial to the Company’s consolidated financial results. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Amounts recorded during the three months ended December 31, 2022 and 2021 were immaterial to the Company's consolidated financial results. The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2022 and September 30, 2022 were as follows: (Millions of dollars) Hedge Designation December 31, 2022 September 30, 2022 Interest rate swaps (a) Fair value hedges $ 700 $ 700 Forward starting interest rate swaps (b) Cash flow hedges 500 500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. (b) Represents interest rate derivatives entered into to mitigate exposure to interest rate risk related to future debt issuances. Other Risk Exposures

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	3 Months Ended
Financial Instruments and Fair Value Measurements	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2022 and September 30, 2022 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) December 31, 2022 September 30, 2022 Cash and equivalents $ 612 $ 1,006 Restricted cash 133 153 Cash and equivalents and restricted cash $ 744 $ 1,159 Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters. The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement December 31, 2022 September 30, 2022 Institutional money market accounts (a) Level 1 $ — $ 1 Current portion of long-term debt (b) Level 2 1,579 1,927 Long-term debt (b) Level 2 12,608 12,119 (a) These financial instruments are recorded within Cash and equivalents on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments. Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year. All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's condensed consolidated balance sheets. Transfers of trade receivables Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements are provided below. Three Months Ended December 31, (Millions of dollars) 2022 2021 Trade receivables transferred to third parties under factoring arrangements $ 740 $ 143 December 31, 2022 September 30, 2022 Amounts yet to be collected and remitted to the third parties $ 314 $ 323

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income Tax Expense The Company’s effective income tax rates for the three months ended December 31, 2022 and 2021 were (5.8)% and 5.3%, respectively. The decrease in the Company’s effective tax rate for the three months ended December 31, 2022 was largely due to a remeasurement of deferred tax assets and liabilities upon the approval of a tax incentive.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contingencies	The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (and in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.
Revenue	Measurement of Revenues The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.
Derivatives	The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes.The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense,
Cash and Cash Equivalents	Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents	Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
Fair Value of Financial Instruments	The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.

Spin-Off of Embecta Corp. (Tabl

Spin-Off of Embecta Corp. (Tables)	3 Months Ended
Spin-Off of Embecta Corp. (Tables)	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	Details of Income from Discontinued Operations, Net of Tax are as follows: Three Months Ended Millions of dollars 2021 Revenues $ 277 Cost of products sold 74 Selling and administrative expense 38 Research and development expense 15 Other operating expense, net 26 Total Operating Costs and Expenses 153 Operating Income 123 Interest expense — Other income, net — Income from Discontinued Operations Before Income Taxes 123 Income tax provision 14 Income from Discontinued Operations, Net of Tax $ 109

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
Shareholders' Equity (Tables)	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of Shareholders Equity	Changes in certain components of shareholders' equity for the first quarters of fiscal years 2023 and 2022 were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2022 $ 365 $ 19,553 $ 15,157 $ 23 (81,283) $ (8,330) Net income — — 509 — — — Common dividends ($0.91 per share) — — (259) — — — Preferred dividends — — (23) — — — Common stock issued for share-based compensation and other plans, net — (52) — — 556 (3) Share-based compensation — 89 — — — — Common stock held in trusts, net (a) — — — — (11) — Balance at December 31, 2022 $ 365 $ 19,590 $ 15,384 $ 24 (80,738) $ (8,333) Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) Net income — — 677 — — — Common dividends ($0.87 per share) — — (248) — — — Preferred dividends — — (23) — — — Common stock issued for share-based compensation and other plans, net — (71) — — 762 19 Share-based compensation — 83 — — — Common stock held in trusts, net (a) — — — — (5) — Repurchase of common stock (b) — 150 — — (462) (150) Balance at December 31, 2021 $ 365 $ 19,435 $ 14,233 $ 24 (79,869) $ (7,855) (a) Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) Represents shares received upon final settlement of an accelerated share repurchase agreement, and the related forward sale contract, entered into during the fourth quarter of fiscal year 2021. T he share repurchases were made pursuant to the repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, for which there is no expiration date. In November 2021, the Board of Directors authorized the Company to repurchase up to an additional 10 million shares of BD common stock, for which there is also no expiration date.
Schedule of Accumulated Other Comprehensive Income (Loss)	The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2023 and 2022 were as follows: (Millions of dollars) Total Foreign Currency Benefit Plans Cash Flow Hedges Balance at September 30, 2022 $ (1,488) $ (987) $ (574) $ 75 Other comprehensive loss before reclassifications, net of taxes (84) (80) — (4) Amounts reclassified into income, net of taxes 12 — 11 1 Balance at December 31, 2022 $ (1,559) $ (1,067) $ (563) $ 73 (Millions of dollars) Total Foreign Currency Benefit Plans Cash Flow Hedges Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10) Other comprehensive income (loss) before reclassifications, net of taxes 34 41 — (7) Amounts reclassified into income, net of taxes 11 — 11 — Balance at December 31, 2021 $ (2,043) $ (1,251) $ (774) $ (17)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share	The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows: Three Months Ended 2022 2021 Average common shares outstanding 283,887 284,685 Dilutive share equivalents from share-based plans 1,453 2,038 Average common and common equivalent shares outstanding – assuming dilution 285,340 286,723 Share equivalents excluded from the diluted shares outstanding calculation: Mandatory convertible preferred stock (a) 5,899 5,965 Share-based plans (b) 1,374 730 (a) Excluded from the diluted shares outstanding calculation because the result would have been antidilutive. (b) Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.

Segment Data (Tables)

Segment Data (Tables)	3 Months Ended
Segment Data (Tables)	Dec. 31, 2022
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Area	Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues. Three Months Ended December 31, (Millions of dollars) 2022 2021 United States International Total United States International Total Medical Medication Delivery Solutions (a) $ 620 $ 419 $ 1,039 $ 620 $ 476 $ 1,096 Medication Management Solutions 564 142 706 484 143 627 Pharmaceutical Systems (a) 119 290 409 102 294 397 Total segment revenues $ 1,303 $ 852 $ 2,154 $ 1,207 $ 913 $ 2,120 Life Sciences Integrated Diagnostic Solutions $ 508 $ 445 $ 952 $ 615 $ 530 $ 1,145 Biosciences 137 212 349 129 209 338 Total segment revenues $ 645 $ 657 $ 1,302 $ 744 $ 739 $ 1,483 Interventional Surgery $ 287 $ 76 $ 363 $ 281 $ 80 $ 361 Peripheral Intervention 236 197 433 217 197 413 Urology and Critical Care 259 74 333 254 87 340 Total segment revenues $ 782 $ 347 $ 1,129 $ 752 $ 363 $ 1,115 Total revenues from continuing operations $ 2,730 $ 1,856 $ 4,586 $ 2,703 $ 2,016 $ 4,718 (a) Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.
Financial Information for Company's Segments	Segment income for the three-month periods was as follows: Three Months Ended (Millions of dollars) 2022 2021 Income from Continuing Operations Before Income Taxes Medical $ 554 $ 572 Life Sciences 433 534 Interventional 301 265 Total Segment Operating Income 1,288 1,371 Acquisition-related integration and restructuring expense (44) (34) Net interest expense (96) (96) Other unallocated items (a) (667) (642) Total Income from Continuing Operations Before Income Taxes $ 481 $ 600

Benefit Plans (Tables)

Benefit Plans (Tables)	3 Months Ended
Benefit Plans (Tables)	Dec. 31, 2022
Retirement Benefits [Abstract]
Net Pension and Postretirement Cost	Net pension cost included the following components for the three-month periods: Three Months Ended (Millions of dollars) 2022 2021 Service cost $ 24 $ 35 Interest cost 35 20 Expected return on plan assets (38) (48) Amortization of prior service credit (2) (4) Amortization of loss 17 16 Settlements — 5 Net pension cost $ 36 $ 24

Business Restructuring Charges

Business Restructuring Charges (Tables)	3 Months Ended
Business Restructuring Charges (Tables)	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Summary of Restructuring Accrual Activity	Restructuring liability activity for the three months ended December 31, 2022 was as follows: (Millions of dollars) Employee Other Total Balance at September 30, 2022 $ 24 $ 11 $ 35 Charged to expense 4 22 26 Cash payments (8) (18) (26) Non-cash settlements — (4) (4) Balance at December 31, 2022 $ 20 $ 11 $ 31

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
Intangible Assets (Tables)	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	Intangible assets consisted of: December 31, 2022 September 30, 2022 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 15,136 $ (6,262) $ 8,874 $ 15,087 $ (5,979) $ 9,108 Customer relationships 4,859 (2,260) 2,599 4,853 (2,170) 2,683 Product rights 104 (79) 25 97 (72) 25 Trademarks 408 (160) 248 408 (155) 253 Patents and other 552 (355) 197 542 (346) 196 Amortized intangible assets $ 21,059 $ (9,116) $ 11,943 $ 20,987 $ (8,723) $ 12,264 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46
Reconciliation of Goodwill by Business Segment	The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2022 $ 10,909 $ 888 $ 12,824 $ 24,621 Purchase price allocation adjustments 3 — — 3 Currency translation 54 10 76 139 Goodwill as of December 31, 2022 $ 10,965 $ 898 $ 12,900 $ 24,763

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	3 Months Ended
Derivative Instruments and Hedging Activities (Tables)	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2022 and September 30, 2022 were as follows: (Millions of dollars) Hedge Designation December 31, 2022 September 30, 2022 Foreign exchange contracts (a) Undesignated $ 1,639 $ 2,766 Foreign currency-denominated debt (b) Net investment hedges 1,801 2,140 Cross-currency swaps (c) Net investment hedges 1,473 910 (a) Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other (expense) income, net , during the three months ended December 31, 2022 and 2021 were immaterial to the Company's consolidated financial results. (b) Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (c) Represents cross-currency swaps which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2022 and September 30, 2022 were as follows: (Millions of dollars) Hedge Designation December 31, 2022 September 30, 2022 Interest rate swaps (a) Fair value hedges $ 700 $ 700 Forward starting interest rate swaps (b) Cash flow hedges 500 500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR.
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows: Three Months Ended (Millions of dollars) 2022 2021 Foreign currency-denominated debt $ (142) $ 49 Cross-currency swaps (80) 30

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	3 Months Ended
Financial Instruments and Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2022 and September 30, 2022 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) December 31, 2022 September 30, 2022 Cash and equivalents $ 612 $ 1,006 Restricted cash 133 153 Cash and equivalents and restricted cash $ 744 $ 1,159
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement December 31, 2022 September 30, 2022 Institutional money market accounts (a) Level 1 $ — $ 1 Current portion of long-term debt (b) Level 2 1,579 1,927 Long-term debt (b) Level 2 12,608 12,119 (a) These financial instruments are recorded within Cash and equivalents on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Transfer of Financial Assets Accounted for as Sales	The amounts transferred and yet to be remitted under factoring arrangements are provided below. Three Months Ended December 31, (Millions of dollars) 2022 2021 Trade receivables transferred to third parties under factoring arrangements $ 740 $ 143 December 31, 2022 September 30, 2022 Amounts yet to be collected and remitted to the third parties $ 314 $ 323

Spin-Off of Embecta Corp. - Add

Spin-Off of Embecta Corp. - Additional Information (Details) $ in Millions	3 Months Ended
	Dec. 31, 2021 USD ($)
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Other Expense	$ 25

Spin-Off of Embecta Corp. - Inc

Spin-Off of Embecta Corp. - Income from Discontinued Operations, Net of Tax (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from Discontinued Operations, Net of Tax	$ 0	$ 109
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		277
Cost of products sold		74
Selling and administrative expense		38
Research and development expense		15
Other operating expense, net		(26)
Total Operating Costs and Expenses		153
Operating Income		123
Interest expense		0
Other income, net		0
Income from Discontinued Operations Before Income Taxes		123
Income tax provision		14
Income from Discontinued Operations, Net of Tax		109
Disposal Group, Including Discontinued Operation, Other Expense		$ 25

Shareholders' Equity - Changes

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Sep. 24, 2013
Beginning balance	$ 25,282
Net income	509	$ 677
Ending balance	$ 25,472
Dividends per Common Share (USD per share)	$ 0.91	$ 0.87
Number of shares authorized to be repurchased (in shares)				10,000
Number of additional shares authorized to be repurchased (in shares)			10,000
Common Stock Issued at Par Value
Beginning balance	$ 365	$ 365
Ending balance	365	365
Capital in Excess of Par Value
Beginning balance	19,553	19,272
Common stock issued for share-based compensation and other plans, net	(52)	(71)
Share-based compensation	89	83
Repurchase of common stock		150
Ending balance	19,590	19,435
Retained Earnings
Beginning balance	15,157	13,826
Net income	509	677
Common dividends	(259)	(248)
Preferred dividends	(23)	(23)
Ending balance	15,384	14,233
Deferred Compensation
Beginning balance	23	23
Ending balance	24	24
Treasury Stock
Beginning balance	$ (8,330)	$ (7,723)
Beginning balance (shares)	(81,283)	(80,164)
Common stock issued for share-based compensation and other plans, net	$ (3)	$ 19
Common stock issued for share-based compensation and other plans, net (in shares)	556	762
Common stock held in trusts, net (in shares)	(11)	(5)
Repurchase of common stock		$ (150)
Repurchase of common stock (in shares)		(462)
Ending balance	$ (8,333)	$ (7,855)
Ending balance (shares)	(80,738)	(79,869)

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ (1,488)	$ (2,088)
Other comprehensive loss before reclassifications, net of taxes	(84)	34
Amounts reclassified into income, net of taxes	12	11
Ending balance	(1,559)	(2,043)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(987)	(1,292)
Other comprehensive loss before reclassifications, net of taxes	(80)	41
Amounts reclassified into income, net of taxes	0	0
Ending balance	(1,067)	(1,251)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(574)	(784)
Other comprehensive loss before reclassifications, net of taxes	0	0
Amounts reclassified into income, net of taxes	11	11
Ending balance	(563)	(774)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	75	(10)
Other comprehensive loss before reclassifications, net of taxes	(4)	(7)
Amounts reclassified into income, net of taxes	1	0
Ending balance	$ 73	$ (17)

Earnings Per Share - Weighted A

Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Average common shares outstanding (shares)	283,887	284,685
Dilutive share equivalents from share-based plans (shares)	1,453	2,038
Average common and common equivalent shares outstanding - assuming dilution (shares)	285,340	286,723
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share equivalents excluded from the diluted shares outstanding calculation (shares)	5,899	5,965
Share Based Compensation
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share equivalents excluded from the diluted shares outstanding calculation (shares)	1,374	730

Contingencies (Detail)

Contingencies (Detail) $ in Thousands	1 Months Ended		3 Months Ended
Contingencies (Detail) $ in Thousands	Aug. 31, 2022 USD ($)	Apr. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) plaintiff lawsuit claim	Sep. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Damages awarded	$ 4,800	$ 255
Loss contingency accrual			$ 2,000,000	$ 2,100,000
GEORGIA
Loss Contingencies [Line Items]
Number of EtO lawsuits filed \| lawsuit			220
Loss Contingency, Number of Plaintiffs \| plaintiff			320
Gwinnett County, Georgia
Loss Contingencies [Line Items]
Number of EtO Sterilization Lawsuits, Allege Injury From Unrelated Defendants \| lawsuit			45
Gwinnett County, Georgia \| Maximum
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value			$ 250
Hernia Product Claims
Loss Contingencies [Line Items]
Pending claims \| claim			32,305

Revenues (Details)

Revenues (Details) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Rebate liability	$ 560	$ 525
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction (in years)	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Products and/or Services
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 2,500
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Consumables
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1,900

Segment Data - Additional Infor

Segment Data - Additional Information (Detail)	3 Months Ended
Segment Data - Additional Information (Detail)	Dec. 31, 2022 segment
Segment Reporting [Abstract]
Number of principal business segments (segment)	3

Segment Data - Revenues by Geog

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenues	$ 4,586	$ 4,718
Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	2,154	2,120
Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,302	1,483
Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	1,129	1,115
United States
Segment Reporting Information [Line Items]
Revenues	2,730	2,703
United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	1,303	1,207
United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	645	744
United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	782	752
International
Segment Reporting Information [Line Items]
Revenues	1,856	2,016
International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	852	913
International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	657	739
International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	347	363
Medication Delivery Solutions \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	1,039	1,096
Medication Delivery Solutions \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	620	620
Medication Delivery Solutions \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	419	476
Medication Management Solutions \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	706	627
Medication Management Solutions \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	564	484
Medication Management Solutions \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	142	143
Pharmaceutical Systems \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	409	397
Pharmaceutical Systems \| United States \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	119	102
Pharmaceutical Systems \| International \| Operating Segments \| Medical
Segment Reporting Information [Line Items]
Revenues	290	294
Integrated Diagnostic Solutions \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	952	1,145
Integrated Diagnostic Solutions \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	508	615
Integrated Diagnostic Solutions \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	445	530
Biosciences \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	349	338
Biosciences \| United States \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	137	129
Biosciences \| International \| Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Revenues	212	209
Surgery \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	363	361
Surgery \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	287	281
Surgery \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	76	80
Peripheral Intervention \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	433	413
Peripheral Intervention \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	236	217
Peripheral Intervention \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	197	197
Urology and Critical Care \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	333	340
Urology and Critical Care \| United States \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	259	254
Urology and Critical Care \| International \| Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Revenues	$ 74	$ 87

Segment Data - Financial Inform

Segment Data - Financial Information for Company's Segments (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Acquisition-related integration and restructuring expense	$ (44)	$ (34)
Income from Continuing Operations Before Income Taxes	481	600
Operating Segments
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	1,288	1,371
Operating Segments \| Medical
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	554	572
Operating Segments \| Life Sciences
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	433	534
Operating Segments \| Interventional
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	301	265
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisition-related integration and restructuring expense	(44)	(34)
Net interest expense	(96)	(96)
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Income (Loss) Before Income Taxes	$ (667)	$ (642)

Benefit Plans (Detail)

Benefit Plans (Detail) - Pension Plans - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 24	$ 35
Interest cost	35	20
Expected return on plan assets	(38)	(48)
Amortization of prior service credit	(2)	(4)
Amortization of loss	17	16
Settlements	0	5
Net pension cost	$ 36	$ 24

Business Restructuring Charge_2

Business Restructuring Charges (Detail) $ in Millions	3 Months Ended
Business Restructuring Charges (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 35
Charged to expense	26
Cash payments	(26)
Ending Balance	31
Other Initiatives
Restructuring Reserve [Roll Forward]
Non-cash settlements	(4)
Employee Termination
Restructuring Reserve [Roll Forward]
Beginning Balance	24
Charged to expense	4
Cash payments	(8)
Ending Balance	20
Employee Termination \| Other Initiatives
Restructuring Reserve [Roll Forward]
Non-cash settlements	0
Other
Restructuring Reserve [Roll Forward]
Beginning Balance	11
Charged to expense	22
Cash payments	(18)
Ending Balance	11
Other \| Other Initiatives
Restructuring Reserve [Roll Forward]
Non-cash settlements	$ (4)

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 21,059	$ 20,987
Accumulated Amortization	(9,116)	(8,723)
Net Carrying Amount	11,943	12,264
Unamortized intangible assets	46	46
Acquired in-process research and development
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	44	44
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	15,136	15,087
Accumulated Amortization	(6,262)	(5,979)
Net Carrying Amount	8,874	9,108
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,859	4,853
Accumulated Amortization	(2,260)	(2,170)
Net Carrying Amount	2,599	2,683
Product rights
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	104	97
Accumulated Amortization	(79)	(72)
Net Carrying Amount	25	25
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	408	408
Accumulated Amortization	(160)	(155)
Net Carrying Amount	248	253
Patents and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	552	542
Accumulated Amortization	(355)	(346)
Net Carrying Amount	$ 197	$ 196

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 365	$ 355

Intangible Assets - Reconciliat

Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) $ in Millions	3 Months Ended
	Dec. 31, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 24,621
Purchase price allocation adjustments	3
Currency translation	139
Goodwill, ending balance	24,763
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	10,909
Purchase price allocation adjustments	3
Currency translation	54
Goodwill, ending balance	10,965
Life Sciences
Goodwill [Roll Forward]
Goodwill, beginning balance	888
Purchase price allocation adjustments	0
Currency translation	10
Goodwill, ending balance	898
Interventional
Goodwill [Roll Forward]
Goodwill, beginning balance	12,824
Purchase price allocation adjustments	0
Currency translation	76
Goodwill, ending balance	$ 12,900

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount of derivative	$ 1,639	$ 2,766
Cross-Currency Swaps \| Net investment hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount of derivative	1,473	910
Interest Rate Swaps \| Fair value hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount of derivative	700	700
Forward Starting Interest Rate Swaps \| Cash flow hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount of derivative	500	500
Foreign Currency-Denominated Debt \| Net investment hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount of derivative	$ 1,801	$ 2,140

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax	$ (80)	$ 41
Foreign Currency-Denominated Debt
Derivative Instruments, Gain (Loss) [Line Items]
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax	(142)	49
Cross-Currency Swaps
Derivative Instruments, Gain (Loss) [Line Items]
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax	$ (80)	$ 30

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 612	$ 1,006
Restricted cash	133	153
Cash and equivalents and restricted cash	$ 744	$ 1,159	$ 2,047	$ 2,392

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Institutional money market accounts	$ 0	$ 1
Current portion of long-term debt	1,579	1,927
Long-term debt	$ 12,608	$ 12,119

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2022
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	1 year

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Trade receivables transferred to third parties under factoring arrangements	$ 740	$ 143
Amounts yet to be collected and remitted to the third parties	$ 314		$ 323

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended
Income Taxes - Additional Information (Details)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Percent	(5.80%)	5.30%